论文部分内容阅读
[目的]评价外周血中性粒细胞与淋巴细胞比率(NLR)和血小板与淋巴细胞比率(PLR)对乳腺癌新辅助化疗疗效的预测价值。[方法]回顾性分析394例接受新辅助化疗(NAC)乳腺癌患者治疗前血液NLR、PLR分布情况,采用受试者工作特征曲线(ROC)法评估NLR、PLR对NAC疗效达病理完全缓解(pCR)的预测价值。[结果]NAC后pCR率为17.0%,pCR组NLR、PLR分别为1.64±0.5、120.7±37.7,非pCR组分别为2.4±1.1、142.0±46.2,组间差异有统计学意义(P﹤0.001);NLR、PLR鉴别pCR的受试者工作特征曲线(ROC)的曲线下面积(AUC)分别为0.75、0.64;NLR(≥1.6)、PLR(≥120.7)预测乳腺癌NAC后pCR率的敏感性分别为76.8%、62.6%,特异性分别为60.3%、62.6%;二分类Logistic回归分析显示NLR水平是NAC疗效的独立预测因素。[结论]治疗前外周血高水平NLR预示乳腺癌NAC后的pCR率更低。
[Objective] To evaluate the predictive value of peripheral blood neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in the treatment of neoadjuvant chemotherapy for breast cancer. [Methods] The distribution of NLR and PLR in blood of 394 breast cancer patients receiving neoadjuvant chemotherapy (NAC) before treatment was retrospectively analyzed. The NLR was evaluated by the receiver operating characteristic curve (ROC) method. The therapeutic effect of PLR was completely relieved pCR) predictive value. [Results] The pCR rate of NCR group was 17.0%. The NLR and PLR of pCR group were 1.64 ± 0.5 and 120.7 ± 37.7 respectively, while those of non-pCR group were 2.4 ± 1.1 and 142.0 ± 46.2 respectively (P <0.001) ). The area under the curve (AUC) of NLR and PLR in patients with pCR were 0.75,0.64, NLR (≥1.6) and PLR (≥120.7), respectively. Sexual differences were 76.8% and 62.6% respectively, specificity was 60.3% and 62.6% respectively. Logistic regression analysis showed that NLR level was an independent predictor of NAC efficacy. [Conclusion] The high level of NLR in peripheral blood before treatment indicates that the pCR rate of NAC after breast cancer is lower.